Which has stronger earnings and valuation, GHRS or AVIR?

GH Research is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$1.00 N/A Atea Pharmaceuticals N/A N/A -$158.35M -$2.08 N/A

Is GHRS or AVIR more profitable?

GH Research's return on equity of -20.86% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -20.86% -20.12% Atea Pharmaceuticals N/A -64.25% -57.12%

Does the media prefer GHRS or AVIR?

In the previous week, GH Research had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for GH Research and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.11 beat GH Research's score of 0.45 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, RAPP or AVIR?

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rapport Therapeutics N/A N/A -$111.48M -$3.04 N/A Atea Pharmaceuticals N/A N/A -$158.35M -$2.08 N/A

Is RAPP or AVIR more profitable?

Rapport Therapeutics' return on equity of -29.02% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Rapport Therapeutics N/A -29.02% -27.37% Atea Pharmaceuticals N/A -64.25% -57.12%

Does the media prefer RAPP or AVIR?

In the previous week, Rapport Therapeutics had 9 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 11 mentions for Rapport Therapeutics and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.11 beat Rapport Therapeutics' score of 0.54 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AVIR or INVA?

In the previous week, Atea Pharmaceuticals and Atea Pharmaceuticals both had 2 articles in the media. Atea Pharmaceuticals' average media sentiment score of 1.11 beat Innoviva's score of 0.93 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PAHC or AVIR?

In the previous week, Phibro Animal Health had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for Phibro Animal Health and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.11 beat Phibro Animal Health's score of 0.50 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRON or AVIR?

In the previous week, Cronos Group had 7 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 9 mentions for Cronos Group and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.11 beat Cronos Group's score of 0.45 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Atea Pharmaceuticals (AVIR) Competitors

$5.15 -0.01 (-0.19%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$5.14 -0.01 (-0.10%)

As of 10/9/2026 07:30 PM Eastern

Compare

AVIR vs. GHRS, RAPP, INVA, PAHC, and CRON

Should you buy Atea Pharmaceuticals stock or one of its competitors? Atea Pharmaceuticals's main competitors and comparable companies include GH Research (GHRS), Rapport Therapeutics (RAPP), Innoviva (INVA), Phibro Animal Health (PAHC), and Cronos Group (CRON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Atea Pharmaceuticals compare to GH Research?

GH Research (NASDAQ:GHRS) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

GH Research is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

GH Research currently has a consensus price target of $45.00, suggesting a potential upside of 113.17%. Atea Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 35.92%. Given GH Research's stronger consensus rating and higher possible upside, analysts clearly believe GH Research is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

56.9% of GH Research shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 41.6% of GH Research shares are owned by insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

GH Research's return on equity of -20.86% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.86%	-20.12%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

In the previous week, GH Research had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for GH Research and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.11 beat GH Research's score of 0.45 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GH Research has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

Summary

GH Research beats Atea Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Rapport Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

In the previous week, Rapport Therapeutics had 9 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 11 mentions for Rapport Therapeutics and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.11 beat Rapport Therapeutics' score of 0.54 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rapport Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 12.5% of Rapport Therapeutics shares are owned by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Rapport Therapeutics currently has a consensus price target of $66.11, indicating a potential upside of 115.70%. Atea Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 35.92%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rapport Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

Rapport Therapeutics' return on equity of -29.02% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-29.02%	-27.37%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

Summary

Rapport Therapeutics beats Atea Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Innoviva?

Atea Pharmaceuticals (NASDAQ:AVIR) and Innoviva (NASDAQ:INVA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Innoviva has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
Innoviva	$411.33M	3.73	$271.17M	$4.10	5.17

Atea Pharmaceuticals presently has a consensus price target of $7.00, indicating a potential upside of 35.92%. Innoviva has a consensus price target of $39.25, indicating a potential upside of 85.05%. Given Innoviva's stronger consensus rating and higher probable upside, analysts plainly believe Innoviva is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Innoviva	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Atea Pharmaceuticals has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 2.0% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Innoviva has a net margin of 81.19% compared to Atea Pharmaceuticals' net margin of 0.00%. Innoviva's return on equity of 28.03% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
Innoviva	81.19%	28.03%	20.19%

In the previous week, Atea Pharmaceuticals and Atea Pharmaceuticals both had 2 articles in the media. Atea Pharmaceuticals' average media sentiment score of 1.11 beat Innoviva's score of 0.93 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innoviva beats Atea Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Phibro Animal Health currently has a consensus price target of $47.67, indicating a potential upside of 24.46%. Atea Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 35.92%. Given Atea Pharmaceuticals' higher possible upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Phibro Animal Health has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52B	1.02	$99.72M	$2.44	15.70
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 48.5% of Phibro Animal Health shares are owned by insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Phibro Animal Health has a net margin of 6.57% compared to Atea Pharmaceuticals' net margin of 0.00%. Phibro Animal Health's return on equity of 37.86% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

In the previous week, Phibro Animal Health had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for Phibro Animal Health and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.11 beat Phibro Animal Health's score of 0.50 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phibro Animal Health has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

Summary

Phibro Animal Health beats Atea Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Cronos Group has a net margin of 39.08% compared to Atea Pharmaceuticals' net margin of 0.00%. Cronos Group's return on equity of 4.85% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	39.08%	4.85%	4.62%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

In the previous week, Cronos Group had 7 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 9 mentions for Cronos Group and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.11 beat Cronos Group's score of 0.45 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cronos Group	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cronos Group has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59M	8.12	-$9.45M	$0.20	16.15
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cronos Group presently has a consensus price target of $2.30, suggesting a potential downside of 28.79%. Atea Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 35.92%. Given Atea Pharmaceuticals' higher probable upside, analysts plainly believe Atea Pharmaceuticals is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Cronos Group has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

Summary

Cronos Group beats Atea Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Atea Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVIR vs. The Competition

Export

Metric	Atea Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$413.45M	$12.35B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.36%
P/E Ratio	-2.48	797.58	274.15	26.16
Price / Sales	N/A	756.50	590.34	94.78
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	1.46	10.71	11.21	6.34
Net Income	-$158.35M	$2.84B	$3.50B	$381.90M
7 Day Performance	0.39%	-0.93%	-0.90%	-1.41%
1 Month Performance	-0.58%	-4.91%	-4.44%	-3.48%
1 Year Performance	64.01%	-4.13%	6.96%	1.16%

Atea Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVIR Atea Pharmaceuticals	2.3478 of 5 stars	$5.15 -0.2%	$7.00 +35.9%	+64.5%	$413.45M	N/A	N/A	55
GHRS GH Research	3.5229 of 5 stars	$24.67 +5.3%	$45.00 +82.4%	+60.2%	$1.61B	N/A	N/A	73	News Coverage High Trading Volume
RAPP Rapport Therapeutics	2.7345 of 5 stars	$33.02 -1.3%	$66.25 +100.6%	+14.6%	$1.60B	N/A	N/A	84	News Coverage Analyst Forecast Insider Trade
INVA Innoviva	3.3928 of 5 stars	$21.11 -0.6%	$34.80 +64.9%	+21.5%	$1.53B	$411.33M	5.15	159	News Coverage
PAHC Phibro Animal Health	4.5859 of 5 stars	$35.45 -0.7%	$47.67 +34.5%	+3.0%	$1.45B	$1.52B	14.53	2,605	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVIR) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. GHRS, RAPP, INVA, PAHC, and CRON

How does Atea Pharmaceuticals compare to GH Research?

Summary

How does Atea Pharmaceuticals compare to Rapport Therapeutics?

Summary

How does Atea Pharmaceuticals compare to Innoviva?

Summary

How does Atea Pharmaceuticals compare to Phibro Animal Health?

Summary

How does Atea Pharmaceuticals compare to Cronos Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. GHRS, RAPP, INVA, PAHC, and CRON

How does Atea Pharmaceuticals compare to GH Research?

Which has stronger earnings and valuation, GHRS or AVIR?

Do analysts rate GHRS or AVIR?

Do institutionals and insiders have more ownership in GHRS or AVIR?

Is GHRS or AVIR more profitable?

Does the media prefer GHRS or AVIR?

Which has more risk and volatility, GHRS or AVIR?

Summary

How does Atea Pharmaceuticals compare to Rapport Therapeutics?

Does the media prefer RAPP or AVIR?

Which has more volatility & risk, RAPP or AVIR?

Do insiders and institutionals have more ownership in RAPP or AVIR?

Do analysts prefer RAPP or AVIR?

Which has stronger valuation & earnings, RAPP or AVIR?

Is RAPP or AVIR more profitable?

Summary

How does Atea Pharmaceuticals compare to Innoviva?

Which has preferable earnings & valuation, AVIR or INVA?

Do analysts prefer AVIR or INVA?

Which has more volatility & risk, AVIR or INVA?

Do institutionals & insiders believe in AVIR or INVA?

Is AVIR or INVA more profitable?

Does the media refer more to AVIR or INVA?

Summary

How does Atea Pharmaceuticals compare to Phibro Animal Health?

Do analysts prefer PAHC or AVIR?

Which has preferable valuation and earnings, PAHC or AVIR?

Do institutionals and insiders have more ownership in PAHC or AVIR?

Is PAHC or AVIR more profitable?

Does the media prefer PAHC or AVIR?

Which has more risk & volatility, PAHC or AVIR?

Summary

How does Atea Pharmaceuticals compare to Cronos Group?

Is CRON or AVIR more profitable?

Does the media prefer CRON or AVIR?

Which has higher valuation and earnings, CRON or AVIR?

Do insiders and institutionals hold more shares of CRON or AVIR?

Do analysts recommend CRON or AVIR?

Which has more volatility and risk, CRON or AVIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools